INTRODUCTION
Malignant transformation occurs as a step-wise process in which genetic and epigenetic aberrations accumulate and lead to progressive alteration of the molecular makeup and function of cells. [1] [2] [3] If initially formed 'pre-malignant' cells are not cleared by the organism, further alterations may ultimately generate fully transformed cells that initiate the cancer, so-called cancer stem cells. As the acquisition of mutations is not a rapid process, it is reasonable to assume that pre-malignant alterations occur either in cells with a long life span, such as tissue-specific stem cells, or the initial mutation has to confer self-renewal ability to a cell with a shorter life span. Recent findings have shown that cancer stem cells can exist as pools of relatively quiescent and long-lived cells that do not respond well to common cell-toxic agents and thereby contribute to disease relapse. 4 Myeloid malignancies also arise from a population of aberrant cells that in most cases are not eliminated by conventional cytotoxic therapies, and which share many cellular features with normal hematopoietic stem cells, such as sustained self-maintenance, proliferative capacity, and some degree of differentiation potential. 5 Various murine models of acute myeloid leukemia have demonstrated that these aberrant cells, capable of initiating the leukemia in lethally irradiated recipient mice (leukemia-initiating cells) can reside within the population of phenotypical hematopoietic stem cells (HSC) [6] [7] [8] [9] but also among lineage-committed progenitor cells. [10] [11] [12] The exact molecular mechanism which ultimately leads to malignant transformation of immature stem and myeloid progenitor cells is, however, still not understood.
Myelodysplastic syndromes (MDS) are considered a 'preleukemic' disease that is characterized by massively impaired hematopoiesis with decreased peripheral blood counts that can affect all blood lineages. While it has been assumed for a long time that MDS is a 'stem cell disease', only recently reports have provided hard evidence for this hypothesis and have described profound alterations in rigorously defined stem and progenitor cells of MDS patients. [13] [14] [15] In addition to quantitative abnormalities, recent findings have revealed molecular alterations in MDS stem cells and demonstrated the persistence of these cells in relapse. 15 As patients with MDS have a significant risk of developing acute myeloid leukemia, understanding the molecular and functional aberrations in hematopoietic stem and progenitor compartments in MDS will not only enable the development of more efficient and durable treatment options, but may also provide valuable insights into the transformation process of acute myeloid leukemias.
MDS-INITIATING CELLS RESIDE IN THE HSC COMPARTMENT, HARBOR CYTOGENETIC ALTERATIONS AND SUPPRESS COEXISTING RESIDUAL NORMAL HSC
Early studies characterizing immature hematopoietic cells in patients with MDS have focused on patients with recurring chromosomal aberrations using fluorescence in-situ hybridization in stem and progenitor cell-enriched compartments. 16 The advent of multi-parameter FACS has enabled studies on more precisely defined stem cells, which in combination with fluorescence in-situ hybridization analysis allow for the separation of normal HSC and stem cells being part of the aberrant clone. Recent studies on patients with À 5q aberrations showed that while only a minority of pro-B and pro-T cells were cytogentically abnormal, the majority of myeloid cells and 95-98% of CD34 þ CD38 À CD90 þ (Thy1) HSC had the cytogenetic defect. Functional studies ex vivo furthermore indicated that the CD34 þ CD38 À HSC compartment harbors disease-relevant cells with 5q deletions. 17 A study of MDS patients with trisomy of chromosome 8 showed that this cytogenetic alteration was not as frequently seen in the CD34 þ CD38 À HSC. 18 Furthermore, examination of patients that had both trisomy 8 and 5q À abnormalities showed that only del(5q) occurred in the more primitive stem cell compartments, suggesting that several clones of aberrant cells organized in a hierarchical fashion reside in the bone marrow of these patients (for overview see Table 1 ). Our own studies on highly purified stem and progenitor populations from MDS patients with À 7/7q-revealed that a very high proportion of precisely defined
and progenitors contained the À 7/7q-abnormality (490%) while unfractionated whole bone marrow cells only showed a mean involvement of 60% of karyoptypically abnormal cells, demonstrating that these alterations are strikingly enriched in stem and progenitor cells in MDS. 15 Interestingly, B and T lymphocytes in MDS patients rarely contain these abnormalities, [19] [20] [21] [22] [23] [24] [25] [26] [27] demonstrating that normal HSC clones must still be present from which lymphocytic cells can originate, and that aberrations occurring in MDS HSC are incompatible with the commitment and differentiation to the lymphoid lineages. Our understanding of the cellular and molecular basis of how MDS HSC gain a growth advantage over residual normal stem cells is still incomplete. Thus, future studies have to focus on elucidating the mechanisms by which abnormal MDS stem cells dominate normal HSC in order to effectively treat the disease and prevent the progression to acute leukemia.
QUANTITATIVE AND FUNCTIONAL CHANGES IN STEM AND PROGENITOR COMPARTMENTS IN MDS
Besides the presence of cytogenetically abnormal cells within the stem cell compartment of patients with MDS, quantitative changes within the stem and immature progenitor compartments of patients with MDS have been reported, revealing compromised hematopoiesis at several stages of immature hematopoietic differentiation in these patients. Interestingly, the well-described clinical heterogeneity of the disease is already reflected at the stem and progenitor cell level as we and others have found alterations in the abundance of different immature hematopoietic stem and progenitor compartments that were specific to certain MDS subtypes, 13, 15, 28 suggesting that subgroups of MDS share common pathophysiologic characteristics. Reduced MEP populations have been observed almost universally in all subtypes of MDS, pointing to a differentiation block or apoptosis prior to this stage, and are in line with the decreased numbers of erythrocytes and platelets, a hallmark of this disease. Several other stem and progenitor cell compartments show subtype-restricted alterations. The bone marrow of patients with lower risk MDS was characterized by a specific expansion of the phenotypic CMP compartment and a relative reduction of MEP and GMP populations, possibly pointing to a differentiation block at this cellular level, while phenotypical HSC varied in frequency more than age-matched controls. 13, 29 One recent study has attributed the reduction in the GMP population seen in lower risk MDS to an enhanced apoptotic cascade with concomitant upregulation of the prophagocytic marker calreticulin, which was found to be specific to the myeloid progenitor compartment. 13 An expansion of the entire Lin À CD34 þ CD38 À stem cell compartment was observed within higher risk subtypes of MDS. 15, 28 This expansion was most pronounced in phenotypically primitive LT-
Patients with higher risk MDS also showed a varying yet significant expansion of the GMP compartment with concomitant expression of the antiphagocytic marker CD47, and a relative decrease of the MEP compartment 13 reminiscent of the alterations in myeloid progenitor population distribution seen in AML. 5, 29 The observation of specific progenitor expansions raise the possibility that these expanded progenitor populations might have a disease-initiating ability. Even though these studies have not been conducted in human MDS, murine models of AML have shown that phenotypic GMP contain the disease-initiating cells. 30 Further studies that test this hypothesis in human MDS and AML are needed and may reveal important Given the significant alterations in stem and progenitor frequencies, differences at the molecular level determined by these studies reflect to a certain point alterations in stem and progenitor cell composition and largely mask underlying disease-relevant alterations. Molecular screening techniques for the detection of mutations, differential gene expression, as well as epigenetic alterations have been constantly refined in the past few years and now enable the comprehensive study of very limited numbers of cells. The continued dissection of the precise stage and subtypespecific molecular alterations in MDS stem and progenitor cells will provide further insight into the evolution of this disease as well as its progression to AML and will reveal targets for specific therapy, which is urgently desired.
Genetic alterations
Studies investigating the mutational status of precisely defined MDS stem and progenitor cells are currently lacking. However, besides well-described karyotypic changes in MDS 31 several recent studies investigating total bone marrow and CD34 þ cells have identified recurrent mutations, including in genes encoding signaling molecules, 1,2 transcriptional, 2 epigenetic 7-9,32 and premRNA splicing factors. 10, 12 A recent comprehensive study by Bejar and colleagues demonstrated that somatic point mutations are common in unfractionated total bone marrow-derived cells in MDS and that 450% of patients carry at least one somatic mutation. 2 They also identified a set of 18 commonly mutated genes, some of which were found associated with specific clinical characteristics. Particularly, mutations in TP53, EZH2, ETV6, RUNX1 and ASXL1 have been identified as independent predictors of poor overall survival in patients with MDS, 2 showing that certain smaller genetic lesions can contribute to the disease pathogenesis. These findings suggest that the extensive cellular heterogeneity hallmarked by a variable presence and severity of cytopenias, aberrant blast cells as well as great differences in the patients' response to treatment, their progression to overt AML, and ultimately survival, is at least in part driven by various combinations of genetic aberrations and different cellular compartments these alterations occur in. To further understand the molecular origin of MDS, future investigations will have to address at which cellular level and in which order these somatic mutations occur, how the disruption of particular genes contribute to the formation, maintenance and the gain of growth advantage of MDS HSC, as well as their contribution to disease relapse.
Transcriptional changes Several studies have utilized transcriptome profiling with gene expression arrays to elucidate the differences between immature hematopoietic cells in MDS in comparison to healthy controls. Early studies were performed on the heterogeneous population of marrow-derived CD34 þ cells from MDS patients and identified MDS-associated gene expression profiles in immature hematopoietic cells. [33] [34] [35] [36] Deregulated transcriptional programs were reported for the three commonest MDS cytogenetic subtypes (del(5q), trisomy 8 and À 7/del(7q)), with Wnt/b-catenin signaling, integrin signaling and cell cycle regulation as the predominant deregulated pathways. 37 In addition, transcriptional changes in CD34 þ cells associated with specific FAB subtypes were reported, including interferon-stimulated genes IFIT4, IFIT1 and IFITM1 showing increased expression. 36 This finding also hints at the important role that cytokines have in the regulation of hematopoietic stem cell self-renewal 38 and, particularly, in bone marrow dysplasia and aplasia syndromes, [39] [40] [41] and which orchestrate apoptotic effects on erythroid progenitor cells, resulting in the pathognomonic refractory anemia. CD34
þ cells of MDS patients with trisomy of chromosome 8 were characterized by deregulation of genes related to immune and inflammatory response such as TGFBR3, IGF-1 and MAF-1. CD34 þ cells from MDS cases with deletions affecting chromosome 7 showed deregulated signaling pathways such as SAPK/JNK, PI3K/ AKT and NF-kB, suggesting enhanced survival mechanisms, and thus worse outcomes in this group. 37 Profiling of more highly enriched HSC (CD34 þ CD38 À CD90 þ ) from MDS patients with 5q À showed that critical regulators of self-renewal, such as BMI1 and Delta-like homolog were upregulated; potentially explaining the growth potential with poor hematopoietic multilineage differentiation capacity of 5q 42 This study also identified the stage-specific downregulation of CCAAT enhancer binding protein-alpha in MDS progenitors (CD34 þ CD38 þ CD90 À ), a gene critical for normal myeloid development and known to be involved in the transformation of cells in AML. The 5q deleted region showed resultant gene dosage effect (downregulation) with reduced levels of TAF7, CDC42SE2 and
Our own group has recently carried out and reported a gene expression analysis using rigorously purified HSC (Lin
þ ) from patients with MDS and age-matched healthy controls, and in conjunction with epigenetic profiling, 15 which is discussed in the next paragraph.
Epigenetic alterations
In addition to transcriptomic changes, epigenetic changes have been found in MDS stem cells. Methylome analysis of CD34 þ cells from MDS patients with the HELP assay revealed widespread hypermethylation in MDS samples. Among the genes aberrantly hypermethylated in MDS when compared with normal CD34 þ cells were those from the WNT signaling pathway, including GSK3b, APC2, SFRP1, SFRP2, SFRP3, FRAT1and AXIN2, as well as genes encoding for Wnt proteins 2b, 3, 4, 5, 6, 9, 10 and 16. 43 We have recently examined the transcriptome and methylome of highly purified HSC (Lin 15 We utilized an optimized version of the HpaII tiny fragment enrichment by ligation-mediated PCR (HELP) assay that could work with nanogram amounts of DNA from sorted cells (nano-HELP assay). 44 In contrast to studies done on whole bone marrow that found predominant hypermethylation in MDS, our study of rigorously sorted HSC shows both aberrant hypo-and hypermethylated loci in MDS. We found aberrant methylation of several genes not previously linked to MDS pathobiology, such as hypermethylated-NOTCH4, RET and DLL3, and hypomethylated NOTCH1, NANOG and HDAC4 in MDS stem cells, thereby providing the first evidence of epigenetic alterations in the earliest definable HSC. These findings suggest that specific target genes are genetically and epigenetically deregulated in early stem and progenitor cells in MDS, which may make these cells therapeutically targetable. Despite considerable inter-sample variability, 9 genes were consistently hypomethylated and overexpressed in MDS-HSC (STAT3, WDR5, OBFC2B, SKA3, HEXA, CIAPIN1, VRK3, CHAF1B and RANBP1). Functional studies of one such target, STAT3, showed that inhibition of STAT3 activation by small molecule inhibitors led to an 82% inhibition of the clonogenic capacity of Lin CD34 þ CD38 À of MDS stem cells while age-matched healthy donor purified HSC were not significantly affected. 15 Taken together, these studies show that MDS HSC harbor epigenetic, transcriptional and karyotypic alterations, which warrant further study in larger clinical cohorts and can be leveraged for the development of targeted, MDS stem cell-directed therapies in the future.
Immunophenotypical alterations of MDS HSC
In order to precisely understand the molecular mechanism by which MDS stem cells dominate normal stem cells and evade current therapies, further characterization of highly purified aberrant and normal stem and progenitor cells are required. Recent and current efforts have focused on the discovery of cell surface marker genes, allowing for the prospective isolation of viable aberrant stem and progenitor cells and subsequently for their functional and molecular characterization. A recent study has identified the glycoprotein CD99 as a distinct surface marker present on MDS HSCs. The expression of CD99 was found predominantly in the CD34 þ CD38 À fraction of stem cells in MDS/ AML, and CD99 þ expressing HSC demonstrated greater colony forming capacity and leukemia initiating cell activity in xenografts. On the contrary, CD99 low expressing colonies showed phenotypic properties resembling normal HSC and MPP and lacked molecular abnormalities. 45 Work from our own laboratory has shown that the surface protein IL1RAP is overexpressed on fractionated HSC from patients with high-risk MDS, but not lowrisk MDS, 46 and may thus represent a novel marker of MDS disease progression at the stem cell level. However, the exact functional relevance of aberrant expression of CD99 and IL1RAP on stem and multipotent progenitors patients with MDS/AML still needs to be determined. Deciphering the cellular and molecular mechanisms that separate aberrant from normal or predisposed stem and progenitor cells will provide novel therapeutic targets for the specific elimination of all transformed, disease-relevant cells.
PRE-LEUKEMIC STEM CELLS IN MDS AND AML
Recent findings in patients including at the minimal residual disease stage and in patients at relapse after achieving complete remission have brought into perspective the existence of preleukemic clones in AML, a feature that is likely shared with MDS. 28, 47, 48 Several studies in AML mouse models have shown strong evidence of mutations in transcription factors to be early events in leukemic clonal evolution. 11, 49, 50 Some of these mutants impair normal gene function and disrupt hematopoiesis by increasing the self-renewing capacity of myeloid progenitors, with targeted expansion of the MPP compartment, prior to progression of overt leukemia, such as AML1-ETO and MLL-AF9. 51, 52 Simultaneously, murine models with diminished expression of key transcription factors (sfi1, Junb, Gata1&2, Hlx, HoxB4, HoxA9, TGF-b, Wnt and Notch) have shown to perpetuate increased HSC numbers, which evade immunological response and are propagated in the niche, primed to undergo subsequent leukemic transformation. 6, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] However, the precise mechanisms that lead to dysregulated expression of key transcription factors in murine and human leukemogenesis are still incompletely understood. Recent work has identified crucial epigenetic regulatory factors that influence the expansion and differentiation of HSC and progenitors. Many gene loss-offunction murine models (Tet2, IDH1&2, EZH2, Dnmt1&3a, Asxl1)
3,63-69 have revealed augmented HSC numbers, skewed myeloid-specific expansion and myelodysplastic features but none of these develop frank leukemia. Recent work has shown that some of these disease alleles cooperate in the initiation of MDS. 70, 71 Deregulated metabolic pathways in murine HSC have also shown to contribute towards the origin of a pre-LSC and leukemogenesis. Loss of genes such as Pten, Pml, Fbxw7, Hif-1b, Lkb1 [72] [73] [74] [75] [76] [77] leads to expansion of the HSC compartment, with gradual development of a myeloproliferative disorder. Taken together, clinical and mouse data have provided strong evidence for the existence of pre-LSC populations, which are involved in disease initiation and also in disease relapse, thus warranting future studies to ultimately permit targeting of these heterogeneous and functionally critical cellular subsets.
ABERRANT HSC AND DISEASE RELAPSE IN MDS
The role of MDS HSC in disease relapse has been most extensively studied in 5q À syndrome. Lenalidomide is an immunomodulatory drug that has been shown to induce hematologic remissions in 67% of patients with 5q À syndrome and is FDA approved for this disease. Unfortunately, there is a high rate of relapse after this treatment. Recently, in del(5q) MDS, rare stem cells, selectively resistant to Lenalidomide were shown to persist at the time of complete clinical and cytogenetic remission.
14 Lenalidomide was more effective in reducing the del(5q) clone in CD34 À /low CD90 þ stem cells, unresponsive to lenalidomide, were found to be quiescent, predominantly in the G0 phase and continued to show no response to cytokine induction. Furthermore, the expression of several genes linked to stem-cell function and leukemic transformation (HOXA9, MEIS1, MCL1, BMI1, C-MYC and MYCN)
14,78-81 and several efflux pumps (ABCB1, ABCB7, and ABCC1) were upregulated in del(5q) CD34 þ CD38
À /low CD90 þ stem cells, possibly contributing to their drug-resistant properties. 81, 82 These cells also exhibited a significant upregulation of cell-surface IL3RA at the time of remission as well as during progression. 14 Our own studies have recently evaluated the role of karyotypically abnormal stem cells during treatment with 5-azacytidine, an agent that is FDA approved for treatment of MDS. 15 Serial examination of bone marrow obtained from a patient treated with a combination of 5-azacytidine and vorinostat revealed the high-level persistence of karyotypically abnormal HSC with the chromosome 7 deletion even at the time of complete morphological remission with normal blood counts and dramatic reduction of À 7 cells in unfractionated bone marrow cells. Expansion of clonotypic HSC preceded a fulminant clinical relapse by two months, strongly suggesting that relapse is driven out of the aberrant stem cell compartment and that the analysis at the stem cell level has diagnostic and prognostic value. These findings provide a cellular explanation of the high relapse rate in high-risk MDS patients treated with epigenetic modifiers such as HDAC and DNMT inhibitors, suggesting that these agents do not lead to the eradication of clonally abnormal HSC in MDS, even upon a very good morphological remission and hematologic recovery.
Another recent study 83 also evaluated the impact of epigenetic modifying drugs 5 0 -azacitidine and valproate on leukemic stem/ progenitor populations, especially LMPP-like (Lin
þ ) cells in patients with high-risk AML and MDS. The authors observed abnormal expansions in these immunophenotypically distinct LSC populations, as high as 12-fold when compared with normal controls after three cycles of treatment, despite morphologic responses and normalization in marrow blast counts. These expansions predated frank morphological relapses as long as eight months. Partial and non-responders showed negligible reduction in their LSC populations, again strongly suggesting the critical importance of these stem cell compartments for initial therapeutic response and relapse rates. Table 2 ).
STEM CELL ALTERATIONS IN MURINE MODELS OF
The commonly deleted region linked with the 5q-syndrome lies within chr5q31 and 5q32 and contains various candidate genes, including the ribosomal protein RPS14 as well as miR-145 and miR146a. Haploinsufficiency of RPS14 was shown to lead to decreased erythropoiesis in an in-vitro RNAi screen 84 and was then modeled in mice. A mouse model with CD74-Nid67 deletion on chromosome 18, which also included the RPS14 gene 85 displays a phenotype consistent with MDS and develops macrocytic anemia. These mice demonstrate impaired progenitor cell production in the BM (reduced CFU-E, CFU-GM, CFU-MK populations) and have reduced absolute cell numbers of HSC, CMP and GMP in both BM and spleen, which is at least in part due to increased rates of p53-mediated apoptosis. Increased rates of stem and progenitor cell apoptosis mimic findings in human 5q-syndrome. miR-145 and miR-146a are expressed abundantly in normal hematopoietic stem and progenitor cells where they repress Toll-interleukin-1 receptor domain-containing adaptor protein and tumor necrosis factor receptor-associated factor-6, respectively. These two non-coding RNAs were recently identified to be lost in bone marrow cells of patients with 5q À MDS, 31, 86 with miR-145 also playing a role in response to treatment. Importantly, in a murine model, loss of miR-145 and miR-146a and overexpression of tumor necrosis factor receptor-associated factor-6 phenocopied several clinical features of 5q À MDS, 31 and targeting of the associated interleukin-1 receptor-associated kinase 1 was recently reported as a promising therapeutic approach in MDS.
87 Nucleophosmin1 (NPM1), is another gene located in the 5q region (despite not being located in the commonly deleted region) and encodes for a nucleolar protein that is known to modulate ribosomal biogenesis and centrosome duplication. While NPM1 mutations are amongst the most frequent genetic alterations in AML, 88, 89 NPM1 is mutated in o5% of MDS patients. 90 Hypomorphic Npm1 þ / À mice were reported to contain amplified immature erythroblastic populations with increased karytotypic abnormalities (tetraploidy) and dysplastic megakaryopoeisis and granulopoesis, thus resembling clinical subsets of MDS. 91, 92 The deletion of Dicer1, an endonuclease essential for microRNA biogenesis, in osteolineage-specific progenitors in the marrow, was reported to lead to the development of leukopenias, alongside variable anemia and thrombocytopenia. 93 Reduced production of the erythrocytic and megakaryocytic lineages in the bone marrow was largely compensated by splenic extra-medullary hematopoiesis. No significant differences in the frequency or functional impairment of immunophenotypically defined HSC (LSK-SLAM) or progenitor cells derived from Dicer flox/flox and Dicer flox/ þ bone marrow was found. However, increased apoptosis was observed in megakaryocyte-erythroid progenitors. The propagation of a myelodysplastic phenotype was governed by immature cells of the osteolineage, in that stromal cells with osterix þ osteocalcin À expression were able to induce dysplastic features in vivo. On the contrary, Dicer gene-ablated terminally differentiated osteoblasts (osteocalcin þ ) could not recapitulate the hematological abnormalities. Dysplastic changes in the marrow of Dicer flox/flox mice were noted as early as 3 weeks, and they further developed myeloid sarcomas and acute monocytic leukemia-like disease. This proposes that a defunct 'marrow-niche' could be the site for a series of events preceding the evolution of a leukemic clone, possibly through its influence on immature hematopoietic cells.
Mutations in the Ten-Eleven Translocation-2 (TET2) gene have been described in MDS and AML patients. 32, 88, 89 The TET2 gene is involved in hydroxylation of 5-methylcytosine (5-mc), 94 ,95 thereby modulating epigenetic patterns. While TET2 mutations with a corresponding decrease in 5-hydroxy methylcytosine have been frequently detected in humans with MDS, MPD, and AML, 32, 89 conditional Tet2 KO models were reported to give rise to a CMMLlike disease. 68 Analysis of the marrow of these mice showed increased replating potential of LSK-CD150
þ HSC with an upregulation of myeloid progenitor markers CD34
þ FCgR þ and increased expression of self-renewal genes including Meis1 and Evi1. Quantitatively, these mice demonstrated an expansion of their HSC (LSK-SLAM) and progenitor (Lin À c-kit þ CD34 þ FCgR þ ) populations in the spleen, but not in the BM. Importantly, bone marrow-derived cells from Tet2 À / À mice had enhanced competitive repopulating capacity in comparison with WT when transplanted and followed-up at 23 weeks. Another recent study 96 carried out a phenotypic characterization of two models, one which was similar to the previous conditional KO model, and the second being a 'gene-trap' Tet2 KO with 20-50% residual expression of Tet2. In addition to many features described in the previous model, the gene trap model showed a differentiation arrest in the erythroid lineage both in the BM and spleen as well as an expansion of immature aberrant B cell compartments and an immature T-cell
Thus, the inactivation of Tet2 may also alter T-and B-cell differentiation in mice.
Mutations in metabolic enzymes such as IDH1 and IDH2 have been found in AML and MDS and are mutually exclusive with TET2 mutants. 3 Mutants of IDH1 (R132) and IDH2 (R140/R172), 7, [97] [98] [99] acquire a neo-catalytic function with production of 2-hydroxyglutarate, an analog of a-ketoglutarate (a-KG). 100, 101 This oncogenic metabolite impairs the catalytic function of a-KGdependent enzymes, including TET2, thereby reversibly decreasing the levels of 5-hydroxymethylcytosine (5-hmc) hmc and leading to DNA hypermethylation and the induction of leukemia.
101 Idh1 (R132H) knock-in transgenic mice generated by a myeloidpromoter (LysM), have been shown to lead to a preferential expansion of Lin À Sca À 1 þ cKit þ cells (LSK) while sparing myeloid progenitor populations (CMP, GMP, MEP) in the BM and spleen of older compared with younger mice. 102 Moreover, the splenic cells had greater propensity to form myeloid colonies than BM cells, suggestive of extra-medullary hematopoiesis, a feature resulting from a dysfunctional marrow niche and pathognomonic of MDS. Extension of these findings in transgenic mice driven by the Vav promoter, showed constitutive expression of the mutation in all hematopoietic cells and further expansion of the aforementioned populations as well as progenitors (including lymphoid progenitors), suggestive of an incomplete differentiation block. Transgenic LSK cells showed 80% increased methylation of CpG, including at loci involved in signaling pathways, hematopoietic differentiation, and leukemic stem cell maintenance. Taken together, these findings demonstrate that IDH1/2 mutations are possibly acquired as early events in an evolving primitive hematopoietic cell, initiating acquisition of key epigenetic changes favoring leukemogenesis and full transformation. Given their role in leukemogenesis, mutant IDH1/ 2 is currently explored as a novel therapeutic target in AML and glioblastoma. [103] [104] [105] Ectopic viral integration 1 (EVI1), a nuclear transcription factor and proto-oncogene has been shown to regulate hematopoietic 
BM from both Tet2
À / À models showed an increase in LSK fraction within this population ST-
. Myeloid progenitor cells, especially CMP and MEP populations, further showed an absolute increase. Peripheral blood and spleen showed a marked amplification in mature myeloid population (CD11b þ Gr1 À ). Erythrocytic lineage showed a differentiation arrest in the spleen and BM, as the population of proerythroblasts (CD71 þ Ter119 þ ) superseded that of late erythroblasts (CD71 lo Ter119 þ ). Lymphoid lineage reflected similar results with an increase only in the immature T-cell thymic population (CD4 À CD8 À ), while B-cell lineage showed a depleted absolute count. Idh1 (Figueroa et al. , 3, 65 Sasaki et al. 102 )
By-product of Idh1 mutant 2HG, an analog of a-KG, inhibits enzymatic activity of TET2. Resulting in global hypermethylation.
Lin À BM/splenic cells showed a 5-fold increase in the LSK population, predominantly the LT-HSC (CD150 þ CD48 À ) and multipotent progenitor population (CD150 À CD48 þ ), of older versus younger mice, while there was no alteration in the progenitor populations (CMP, GMP, CLP, MEP). Moreover, KI splenic cells showed enhanced myeloid-CFC assays when compared with BM samples (within normal limits). Repopulation KI-BM assays showed no diminished capacity at 170 days post-transplantation. Evi1 (Buonamici et al., Moreover, Sca-1 promoter-driven Evi1 transgenic mice [107] [108] [109] showed a predominant reduction in the erythroid lineage with a decrease in CFU-E colonies, and an expansion in immature erythroid precursors in the BM and spleen albeit circulating RBC were within normal limits and other lineages were unaffected. The underlying mechanism has been attributed majorly to the repression in transcriptional activity of GATA1 and GATA2 with resultant decreased responsiveness to erythropoeitin. 110, 111 Ectopic expression of Evi1 also resulted in susceptibility toward developing myeloid leukemia in newborn mice.
109
Nucleoporin (NUP98) translocations have been associated with some cases of MDS and therapy-related MDS (1-2%). 112 Physiologically, NUP98 acts as a docking site for 'karyopherins', a group of nuclear transport signal receptor proteins, and regulates the nucleo-cytoplasmic shuttling of proteins and RNA.
113 NUP98 fusion partners in MDS or AML include HOXD11 and HOXD13. 114, 115 Nup98-Hoxd13 (Nhd13) transgenic mice 116, 117 develop a fulminant MDS-like disease with transformation into acute leukemia and mortality within 14 months. Lin À bone marrow nucleated cells from Nhd13 mice showed a severe reduction in CFU-GM and CFU-GEMM colony formation when compared with WT Lin À bone marrow nucleated cells. Functional studies demonstrated impaired differentiation from Lin À cells in Nhd13 mice when compared with WT controls. Interestingly, a higher percentage of apoptotic cells was detected by flow analysis within the Nhd13 Lin À bone marrow nucleated cells in culture when supplemented with cytokines (IL-3, IL-6, SCF), consistent with the view that these cells have an impaired ability to differentiate and undergo apoptosis when exposed to differentiating cytokines.
MDS has been associated with SALL4B overexpression and increased SALL4 expression is also seen in up to 60% of M1 and M2 subtypes of AML. 118 Transgenic mice with Sall4 overexpression 118 developed MDS-phenotype in 6-8 months and 50% of cases progressed towards AML. Bone marrow, spleen and lymph node (LN) samples showed an increased positivity for c-kit þ progenitor cells and a higher expression of myeloid markers such as Gr-1 and Mac-1.
Even though these mouse models have shown stem cell dysfunction and other features consistent with MDS, most models are still limited by incomplete penetrance, mixed MPD/MDS phenotypes and highly variable rates of disease penetrance and transformation to acute leukemia.
MODELING OF HUMAN MDS
Primary MDS stem cells have shown reduced xenografting capabilities in several studies (for overview see Table 3 ). Early studies with CD34 þ CD38 À cell populations from patients with 5q deletion demonstrated engraftment from only 1 out of 5 MDS patients. The sample that engrafted, involved transplantation of 700 000 CD34 þ cells and showed as much as 12% human CD45 þ engraftment. 17 Similar studies conducted by the same group in MDS patients with the trisomy 8 defect have shown no engraftment in 17 mice transplanted with CD34 18 Low proportions of engrafted cells were also observed in a larger study that transplanted marrow-derived MDS cells into NOD/SCID-b2m null mice. 119 The engraftment observed was also short lived and mainly myeloid with very few human lymphoid cells. Transplantation in NOD/SCIDb2m null mice engineered to produce human interleukin-3, granulocyte-macrophage colony-stimulating factor and stem cell factor resulted in worse engraftment, suggesting that lack of these human cytokines was not the reason for poor xenotransplantation potential of MDS cells. A modification of this approach was used by Deeg and Coworkers 120 who injected a total of 10 million whole BMMC derived from 6 MDS patients into the femurs of NOD/SCID-b2m null mice along with 1 Â 10 5 cells each of human stromal-derived cell lines (HS5 and HS27a), previously well characterized. 121, 122 Of the 15 mice injected, 11 showed evidence of engraftment. 95% of cells in all but 1 of the 6 mice showed evidence of clonal precursors, which included del(5q), del(7q) and loss of Y chromosome, and at high frequencies which had not been previously demonstrated. The higher rates of clonal cells were attributed not only to the intrafemoral route of transplantation but also to the co-injection of human stromal cells that provide crucial auxiliary signals facilitating engraftment.
A recent study 123 reported that intramedullary injection of bone marrow CD34 þ hematopoietic cells obtained from patients with MDS or AML-MRC (AML with MDS-related changes) into the bone marrow of NOG mice with human MSC improved engraftment of human cells in the murine microenvironment. Lineage analysis revealed a CD33 þ myeloid dominant differentiation in half of the MDS cases and up to 40% of the AML-MRC cases, suggesting the engraftment of MDS-originated cells. This engraftment was also significantly enhanced by the auxiliary delivery of MSC, as mice transplanted with bone marrow CD34 þ and MSC expressed a greater fraction of CD33 þ cells than controls. In contrast, [124] [125] [126] Cytology and bone marrow histology of the xenografted mice revealed that the marrow compartment was filled with large human CD45 þ leukemic blasts. Particularly, the endosteal region of the marrow was enriched with human CD34 þ cells, indicating an invasion of hematopoietic stem cell niches by MDS-originated CD34 þ cells. A study from our own laboratory used NOD-SCID IL2 receptor gamma null mice and found engraftment of BM MNC from a highrisk MDS patient, and that this model could be utilized for preclinical drug testing. 127 Finally, a recent study has shown that FACS-sorted MDS HSC can engraft irradiated, newborn NOD-SCID IL2 receptor gamma null recipient mice transplanted with as few as 1000 purified HSC. 13 The engraftment in these mice was shown to last 412 weeks and resulted predominantly in myeloid progeny. Karyotypic analysis revealed a small but consistent number of aberrant cells, suggestive of no competitive disadvantage of MDS HSC in the xenotransplantation assay. Altogether, these studies show that MDS stem cells do not engraft very well in murine models, though it is possible that the use of more immunodeficient or younger mice may enhance xenografting abilities of MDS cells. These, and even more refined models which are currently being developed, will greatly enhance our ability to study human MDS (stem) cells in the preclinical setting, determine their susceptibility to existing and new treatments, and identify new compounds and drug combinations that are effective at the level of disease-initiating (stem) cells and which may lead to a longer lasting control of the disease.
CONCLUSION
Much of our previous understanding of MDS stem cells was based on and inferred from studies in AML. Utilizing both genetically engineered mouse models as well as patients with human MDS, recent work has provided clear evidence of stage-specific quantitative and qualitative, cell-autonomous alterations of HSC and progenitors in MDS (for overview see Figure 1 ). Even though human MDS stem cells are still hard to xenograft, newer immuno-deficient mice and novel transplantation strategies have been developed, which are instrumental in the molecular and functional study of MDS stem cells. Translational studies have shown that clonally abnormal stem cells can survive during clinical remissions and can predict relapses following standard therapies. It will be critical to continue to study these disease-driving cell populations, and to develop strategies to specifically target them in order to achieve lasting remissions and possibly a cure of the disease in the future.
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